AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Cash from Financing Activities came in at $821000.0 in Q1 2026, down 98.62% year-on-year from $59.6 million in Q1 2025, and down 98.62% quarter-over-quarter from $59.6 million in Q1 2025.
AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 6 years of Cash from Financing Activities data on file, last reported at $59.7 million in Q3 2025.
- For the quarter ending Q3 2025, Cash from Financing Activities rose 1120.76% year-over-year to $59.7 million; the trailing twelve-month figure through Sep 2025 stood at $127.3 million (up 4026.57% YoY), and the FY2024 full-year result was $5.4 million, up 164.32% from the prior year.
- Cash from Financing Activities slipped to $821000.0 in Q1 2026 per ATAI's latest filing, from $59.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $59.6 million in Q1 2025 and bottomed at $821000.0 in Q1 2026.
- A 5-year average of $32.6 million and a median of $1.8 million in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities slumped 817.68% in 2023 and surged 2279.45% in 2025, its largest moves.
- Tracing ATAI's Cash from Financing Activities over 5 years: stood at $1.7 million in 2021, then sank by 153.51% to -$922000.0 in 2022, then tumbled by 817.68% to -$8.5 million in 2023, then soared by 101.82% to $154000.0 in 2024, then surged by 38694.81% to $59.7 million in 2025.
- Business Quant data shows ATAI's Cash from Financing Activities at $59.7 million in Q3 2025, $7.8 million in Q2 2025, and $59.6 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | 59.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 821,000.00 |
| Mar 31, 2026 | 821,000.00 |
| Sep 30, 2025 | 59.74 Mn |
| Sep 30, 2025 | 59.74 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Dec 31, 2024 | 154,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Dec 31, 2023 | -8.46 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Jun 30, 2023 | -100,000.00 |
| Jun 30, 2023 | -100,000.00 |